| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
9,260 |
8,896 |
$1.43M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
8,556 |
8,200 |
$1.30M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
4,792 |
4,459 |
$1.01M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
5,209 |
4,482 |
$844K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,348 |
5,079 |
$794K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,808 |
2,719 |
$605K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
2,449 |
2,398 |
$560K |
| G0378 |
Hospital observation service, per hour |
1,926 |
1,878 |
$556K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
3,195 |
3,097 |
$498K |
| 80053 |
Comprehensive metabolic panel |
15,775 |
13,940 |
$299K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,201 |
1,179 |
$282K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
988 |
962 |
$186K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,008 |
847 |
$140K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
3,405 |
3,322 |
$123K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,526 |
1,446 |
$112K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
721 |
679 |
$109K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
372 |
371 |
$97K |
| 36415 |
Collection of venous blood by venipuncture |
18,848 |
15,596 |
$95K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
172 |
172 |
$93K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,428 |
1,404 |
$62K |
| 86850 |
|
2,126 |
2,052 |
$57K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,501 |
1,436 |
$51K |
| 86900 |
|
2,128 |
2,051 |
$48K |
| 86901 |
|
2,129 |
2,052 |
$48K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
133 |
133 |
$43K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
375 |
68 |
$43K |
| 83880 |
|
1,668 |
1,628 |
$42K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,551 |
1,479 |
$33K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,030 |
1,906 |
$30K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
5,986 |
5,507 |
$28K |
| 95806 |
|
334 |
327 |
$28K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
148 |
148 |
$27K |
| 96367 |
|
668 |
577 |
$26K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,342 |
2,057 |
$24K |
| J3490 |
Unclassified drugs |
2,042 |
1,664 |
$22K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
87 |
68 |
$21K |
| 81025 |
|
7,884 |
7,431 |
$20K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
6,783 |
5,958 |
$19K |
| 85610 |
|
5,402 |
5,177 |
$18K |
| 87631 |
|
381 |
375 |
$18K |
| J0248 |
Injection, remdesivir, 1 mg |
30 |
14 |
$16K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
235 |
230 |
$16K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
245 |
243 |
$13K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
300 |
294 |
$13K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
331 |
322 |
$9K |
| M0222 |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring |
48 |
42 |
$9K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
358 |
313 |
$8K |
| 71046 |
Radiologic examination, chest; 2 views |
1,923 |
1,882 |
$8K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
6,207 |
5,456 |
$7K |
| 80061 |
Lipid panel |
729 |
702 |
$7K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
5,409 |
2,743 |
$7K |
| 84702 |
|
2,056 |
1,977 |
$7K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
27 |
13 |
$5K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
13,593 |
11,866 |
$5K |
| 71045 |
Radiologic examination, chest; single view |
3,989 |
3,828 |
$5K |
| 87581 |
|
331 |
323 |
$5K |
| 87486 |
|
330 |
322 |
$5K |
| 85027 |
|
1,889 |
1,758 |
$4K |
| 90715 |
|
194 |
194 |
$4K |
| 88304 |
|
138 |
137 |
$4K |
| 80050 |
General health panel |
163 |
159 |
$4K |
| 12001 |
|
12 |
12 |
$4K |
| 87088 |
|
5,614 |
5,373 |
$3K |
| 76830 |
Ultrasound, transvaginal |
52 |
52 |
$3K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
635 |
620 |
$3K |
| 96376 |
|
1,467 |
1,167 |
$3K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
81 |
79 |
$2K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
8,718 |
7,721 |
$2K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
17 |
13 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
632 |
543 |
$2K |
| 73630 |
|
308 |
288 |
$2K |
| 82947 |
|
2,482 |
1,634 |
$2K |
| 80076 |
|
134 |
134 |
$1K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
14 |
13 |
$1K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
81 |
79 |
$1K |
| 85730 |
|
4,717 |
4,515 |
$1K |
| 81003 |
|
7,203 |
6,855 |
$1K |
| 83735 |
|
8,922 |
7,981 |
$1K |
| 87070 |
|
856 |
837 |
$1K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
1,420 |
1,362 |
$943.85 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
85 |
82 |
$882.98 |
| 84484 |
|
5,749 |
4,333 |
$849.86 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
323 |
319 |
$774.34 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
85 |
84 |
$639.80 |
| 87186 |
|
547 |
521 |
$630.35 |
| 87077 |
|
558 |
533 |
$577.50 |
| 83690 |
|
4,803 |
4,454 |
$524.92 |
| 84100 |
|
6,730 |
6,172 |
$351.39 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,993 |
1,692 |
$347.82 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,985 |
3,481 |
$343.43 |
| 87040 |
|
2,487 |
1,250 |
$330.81 |
| 82550 |
|
2,376 |
2,246 |
$294.08 |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,077 |
1,037 |
$293.94 |
| 83605 |
|
2,306 |
1,962 |
$285.63 |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
14 |
13 |
$242.48 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
364 |
343 |
$186.20 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
12 |
12 |
$172.80 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
610 |
540 |
$145.06 |
| 82077 |
|
825 |
771 |
$134.85 |
| 85379 |
|
971 |
953 |
$111.51 |
| J2704 |
Injection, propofol, 10 mg |
1,372 |
1,053 |
$107.57 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
799 |
653 |
$94.67 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
6,144 |
4,027 |
$83.20 |
| 80143 |
|
146 |
140 |
$80.43 |
| S0028 |
Injection, famotidine, 20 mg |
1,538 |
1,401 |
$80.27 |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
366 |
333 |
$75.80 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
655 |
555 |
$59.87 |
| 80179 |
|
132 |
127 |
$58.16 |
| J0136 |
Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg |
776 |
694 |
$54.62 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
55 |
55 |
$52.32 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,471 |
1,268 |
$51.87 |
| 73030 |
|
52 |
39 |
$51.65 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
920 |
900 |
$50.35 |
| 74019 |
|
14 |
13 |
$48.59 |
| J7050 |
Infusion, normal saline solution, 250 cc |
938 |
645 |
$47.11 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
68 |
58 |
$46.20 |
| 73562 |
|
88 |
86 |
$40.77 |
| 73610 |
|
60 |
56 |
$37.84 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
63 |
61 |
$31.36 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
1,778 |
1,642 |
$29.40 |
| 85007 |
|
134 |
123 |
$29.09 |
| 84439 |
|
44 |
40 |
$25.48 |
| 84145 |
|
204 |
197 |
$23.39 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
876 |
860 |
$22.86 |
| J2800 |
Injection, methocarbamol, up to 10 ml |
454 |
435 |
$18.10 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
1,406 |
1,224 |
$16.51 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
127 |
124 |
$13.56 |
| 73130 |
|
96 |
93 |
$12.63 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
100 |
67 |
$11.40 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
752 |
700 |
$8.76 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
85 |
85 |
$3.52 |
| J2060 |
Injection, lorazepam, 2 mg |
242 |
210 |
$3.33 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
21 |
20 |
$1.20 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
45 |
39 |
$0.90 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
13 |
13 |
$0.00 |
| J3360 |
Injection, diazepam, up to 5 mg |
33 |
14 |
$0.00 |
| 84436 |
|
139 |
139 |
$0.00 |
| 87276 |
|
29 |
29 |
$0.00 |
| 86141 |
|
15 |
14 |
$0.00 |
| 87275 |
|
29 |
29 |
$0.00 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
14 |
12 |
$0.00 |
| 99080 |
|
75 |
13 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
13 |
13 |
$0.00 |
| 73110 |
|
15 |
13 |
$0.00 |